Whole-person Assessment of Response and Risk after transformative therapies: Investigating Outcomes and Resilience in Sickle Cell Disease (WARRIOR-SCD)
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $20,000,000 to $50,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
-
- Lisbeth Welniak lis.welniak@nih.gov
- Elizabeth R Bulger elizabeth.bulger@nih.gov (301) 000-0000
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, will solicit contractor support for the WARRIOR-SCD (Whole-person Assessment of Response and Risk after transformative therapies: Investigating Outcomes and Resilience in Sickle Cell Disease) study beginning May 1, 2027, with award anticipated in April 2028. The contractor will build and maintain a cohort of individuals with sickle cell disease who have received gene therapy or hematopoietic cell transplantation and sustain long-term follow-up activities for enrolled participants, with the objective of establishing comparative safety, durability, and effectiveness data between these two transformative therapies and against untreated persons with sickle cell disease who declined intervention.
The estimated award value ranges from $20 million to $50 million. This is a new requirement under NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences), with no set-aside category applied. Medical College of Wisconsin is the incumbent contractor. Points of contact are Lisbeth Welniak (lis.welniak@nih.gov) and Elizabeth Bulger (elizabeth.bulger@nih.gov, 301-435-0374).
Forecast text
The National Heart, Lung, and Blood Institute (NHLBI) requires contractor support to continue building a cohort of individuals with sickle cell disease (SCD) who have received gene therapy (GT) or hematopoietic cell transplantation (HCT) and to sustain long-term follow-up (LTFU) activities for enrolled participants. While both therapies are available, it has not been established which is safer, more durable, or most effective, nor have rigorous comparisons to untreated persons with SCD who have chosen not to undergo one of these treatments undertaken.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast